Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia

被引：0
|
作者：
Akiko Mita
Maiko Abumiya
Masatomo Miura
Takenori Niioka
Saori Takahashi
Tomoko Yoshioka
Yoshihiro Kameoka
Naoto Takahashi
机构：
[1] Akita University Graduate School of Medicine,Department of Hematology, Nephrology, and Rheumatology
[2] Akita University Hospital,Department of Pharmacy
[3] Akita University Hospital,Clinical Research Promotion and Support Center
来源：
Experimental Hematology & Oncology | / 7卷
关键词：
Bosutinib; Diarrhea; Liver dysfunction; Trough concentration; Chronic myeloid leukemia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia
    Mita, Akiko
    Abumiya, Maiko
    Miura, Masatomo
    Niioka, Takenori
    Takahashi, Saori
    Yoshioka, Tomoko
    Kameoka, Yoshihiro
    Takahashi, Naoto
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2018, 7
  • [2] Inflammatory/Immune Adverse Events in Chronic Myeloid Leukemia Patients During Treatment With Bosutinib
    Agostani, E.
    Tassistro, E.
    Antolini, L.
    Gambacorti-Passerini, C.
    CANCER MEDICINE, 2025, 14 (03):
  • [3] Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
    Kota, Vamsi
    Brummendorf, Tim H.
    Gambacorti-Passerini, Carlo
    Cortes, Jorge E.
    Lipton, Jeffrey H.
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    An, Fiona
    Leip, Eric
    Crescenzo, Rocco J.
    Woloj, Mabel
    Shapiro, Mark
    Khoury, H. Jean
    BLOOD, 2016, 128 (22)
  • [4] Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib.
    Deininger, Michael W.
    Brummendorf, Tim H.
    Milojkovic, Dragana
    Cervantes, Francisco
    Huguet, Francoise
    Viqueira, Andrea
    Leip, Eric
    Purcell, Simon
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Optimizing Dose of Bosutinib to Minimize Adverse Events While Maintaining Efficacy in Patients with Newly Diagnosed Chronic Myelogenous Leukemia
    Garrett, May
    Knight, Beverly
    Cortes, Jorge E.
    Deininger, Michael W.
    BLOOD, 2017, 130
  • [6] Phase III Randomized Study of Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia Comparing Standard Dose-Escalation with Progressive Dose-Escalation (JALSG CML207 study)
    Miyamura, Koichi
    Ohtake, Shigeki
    Ohnishi, Kazunori
    Usui, Noriko
    Nakaseko, Chiaki
    Fujita, Hiroyuki
    Fujisawa, Shin
    Sakura, Toru
    Okumura, Hirokazu
    Hatta, Yoshihiro
    Emi, Nobuhiko
    Naoe, Tomoki
    BLOOD, 2016, 128 (22)
  • [7] Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study
    Perez-Lamas, Lucia
    Arias, Raquel de Paz
    Diaz, Rosa M. Ayala
    Montero, Luis Felipe Casado
    Payer, angel Ramirez
    Sierra, Magdalena
    Marin, Francisca Ferrer
    Lopez, Raul Perez
    Cirici, Blanca Xicoy
    Steegmann, Juan Luis
    Casares, Maria Teresa Gomez
    Martinez-Lopez, Joaquin
    Garcia-Gutierrez, Valentin
    ANNALS OF HEMATOLOGY, 2024, 103 (10) : 4045 - 4055
  • [8] Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
    Jorge E. Cortes
    Jane F. Apperley
    Daniel J. DeAngelo
    Michael W. Deininger
    Vamsi K. Kota
    Philippe Rousselot
    Carlo Gambacorti-Passerini
    Journal of Hematology & Oncology, 11
  • [9] Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
    Cortes, Jorge E.
    Apperley, Jane F.
    DeAngelo, Daniel J.
    Deininger, Michael W.
    Kota, Vamsi K.
    Rousselot, Philippe
    Gambacorti-Passerini, Carlo
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [10] Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation
    Miyamura, Koichi
    Ohnishi, Kazunori
    Ohtake, Shigeki
    Usui, Noriko
    Nakaseko, Chiaki
    Fujita, Hiroyuki
    Fujisawa, Shin
    Sakura, Toru
    Okumura, Hirokazu
    Iriyama, Noriyoshi
    Emi, Nobuhiko
    Fujimaki, Katsumichi
    Honda, Sumihisa
    Miyazaki, Yasushi
    Naoe, Tomoki
    BLOOD ADVANCES, 2019, 3 (03) : 312 - 319
12345